Review
Biotechnology & Applied Microbiology
Marlene Pluess, Silvia Piantoni, Bjoern Tampe, Alfred H. J. Kim, Peter Korsten
Summary: Advances in the treatment and management of systemic lupus erythematosus have improved patient outcomes, but lupus nephritis remains a major complication. Belimumab has been shown to be superior as an add-on therapy for lupus nephritis, and personalized treatment options are expected with the development of new therapeutic agents.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Medicine, General & Internal
Jasvinder A. Singh, Nipam P. Shah, Amy S. Mudano
Summary: Belimumab at the FDA-approved dose of 10 mg/kg may be associated with a clinically meaningful efficacy benefit compared to placebo in participants with SLE. More data are needed for the longer-term efficacy of Belimumab.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Cell Biology
Tania Colasanti, Francesca Romana Spinelli, Cristiana Barbati, Fulvia Ceccarelli, Susanna Scarpa, Marta Vomero, Cristiano Alessandri, Guido Valesini, Fabrizio Conti
Summary: This study investigates the impact of Belimumab (BLM) on autophagy and citrullination, finding that BLM treatment can decrease autophagy and citrullination levels in patients with SLE, as well as affect IL-18 concentration.
Review
Immunology
Feng Chen, Ying Zheng, Xinying Chen, Zhanfa Wen, Youjia Xu, Jinghua Yang, Kaisi Xu
Summary: Belimumab is an important medication for the treatment of cSLE. However, there is a lack of sufficient research on its efficacy and safety, and further studies are needed to validate its clinical value.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Liping Xu, Xinwei Song, Qiaoding Dai, Tianrong Guan, Yan Zhang, Na Lin, Ji-an Wang
Summary: This case report highlights the efficacy of Belimumab in treating refractory Lupus Cystitis, with significant improvements in symptoms, urinary markers, and protein levels observed in the patient. No relapse of lupus cystitis or SLE activity occurred during the 10-month follow-up period, demonstrating positive outcomes with Belimumab treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Rheumatology
Fan Yang, Jin Lin, Weiqian Chen
Summary: Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by multiple autoantibodies and immune-mediated tissue damage. While a new drug, belimumab, shows promise in improving SLE conditions, the discovery of novel therapeutic targets is urgently needed. Protein post-translational modifications (PTMs) may play key roles in regulating T-cell function and signaling pathways in SLE pathogenesis, presenting potential new targets for therapy.
Article
Immunology
Hao Cheng, Xiao-ying Zhang, Hui-dan Yang, Zhen Yu, Cheng-lan Yan, Chong Gao, Hong-yan Wen
Summary: This study showed that Belimumab in combination with low-dose intravenous CYC significantly reduced disease activity scores and maintained the B/T cell balance for SLE patients at 24 weeks. The Belimumab treatment group had lower adverse events and higher efficacy compared to conventional treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jing Wang, Bomiao Ju, Li Zhu, Hanchao Li, Jing Luo, Jing Zhang, Nan Hu, Lingfei Mo, Yanhua Wang, Ying Pan, Jing Huang, Xiaohong Lv, Dan Pu, Zhiming Hao, Lan He, Yuanyuan Li
Summary: The study aimed to examine the kinetics of B cell subsets and activation markers in the early stage of belimumab treatment and their correction with treatment response. Flow cytometry was used to test the B cell subsets and activation markers of 27 systemic lupus erythematosus (SLE) patients receiving 6 months belimumab treatment. The results showed that B cell hyperactivity was rapidly inhibited in the early stage of belimumab treatment and the ratio of p-SYK/p-AKT may predict SLEDAI-2K decline.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Roberto Depascale, Mariele Gatto, Margherita Zen, Francesca Saccon, Maddalena Larosa, Elisabetta Zanatta, Sara Bindoli, Andrea Doria, Luca Iaccarino
Summary: Belimumab, a fully humanized monoclonal antibody targeting B cells, has demonstrated efficacy and safety in clinical practice. Questions regarding the timing of its use, discontinuation, and potential combination with other biological drugs require further investigation.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Rheumatology
Yusuke Miyazaki, Shingo Nakayamada, Koshiro Sonomoto, Kawabe Akio, Yoshino Inoue, Naoaki Okubo, Shigeru Iwata, Kentaro Hanami, Yoshiya Tanaka
Summary: This study investigated the efficacy and safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE) during maintenance therapy. The results showed that BEL combined with standard-of-care therapy was effective in reducing glucocorticoid (GC) dosage and relapse rate in SLE patients. The study also identified factors associated with successful tapering of GC dosage.
Article
Biochemistry & Molecular Biology
Mingxin Bai, Liling Xu, Huaqun Zhu, Jimeng Xue, Tian Liu, Feng Sun, Haihong Yao, Zhen Zhao, Ziye Wang, Ranran Yao, Fanlei Hu, Yin Su
Summary: This study revealed a decrease in GrB-producing Bregs in SLE patients, which correlated with clinical and immunological features. Furthermore, these cells exhibited impaired function under SLE conditions. The negative correlation between GrB-producing Bregs and CD4(+) T cells observed in healthy individuals disappeared in SLE patients.
MOLECULAR IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ioannis Parodis, Alvaro Gomez, Julius Lindblom, Jun Weng Chow, Christopher Sjowall, Savino Sciascia, Mariele Gatto
Summary: This study investigated changes in B cell subsets in relation to renal flares in SLE patients undergoing standard therapy plus belimumab or placebo. The study found that a rapid drop followed by a subsequent return in circulating short-lived plasma cells and plasmablasts upon treatment for active extra-renal SLE indicated the occurrence of renal flares. Rapid decreases in transitional B cells and peripheral long-lived plasma cells upon belimumab therapy commencement may signify a greater protection against renal flares.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Ioannis Parodis, Alvaro Gomez, Jun Weng Chow, Alexander Borg, Julius Lindblom, Mariele Gatto
Summary: This study found that early changes in certain B cell subsets and anti-dsDNA levels in patients with systemic lupus erythematosus upon treatment initiation may herald subsequent severe disease flares. Rapid expansion of memory B cells may signify sustained response to therapy, while no return or delayed increases in memory B cells may indicate flare development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Muhammad Shipa, Andrew Embleton-Thirsk, Mariea Parvaz, Liliana Ribeiro Santos, Patrick Muller, Kashfia Chowdhury, David A. Isenberg, Caroline J. Dore, Caroline Gordon, Michael R. Ehrenstein
Summary: In patients with refractory systemic lupus erythematosus (SLE), the use of belimumab following rituximab significantly reduced serum IgG anti-dsDNA antibody levels and decreased the risk of severe disease flares, suggesting the potential for this combination as a therapeutic strategy.
ANNALS OF INTERNAL MEDICINE
(2021)
Review
Immunology
Swayanka Biswas, Katja Bieber, Rudolf Armin Manz
Summary: IL-10 is a cytokine that has pleiotropic effects on immune cells, including both suppressive and activating functions. It plays a dual role in Systemic lupus Erythematosus (SLE), inhibiting pro-inflammatory effector functions while also promoting extrafollicular antibody response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, and it drives B cell responses, proliferation, class switching, and plasma cell formation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Terry-Ann M. Milford, Ruijun J. Su, Olivia L. Francis, Ineavely Baez, Shannalee R. Martinez, Jacqueline S. Coats, Abby J. Weldon, Milcris N. Calderon, Michael C. Nwosu, Allen R. Botimer, Batul T. Suterwala, Xiao-Bing Zhang, Christopher L. Morris, David J. Weldon, Sinisa Dovat, Kimberly J. Payne
EUROPEAN JOURNAL OF IMMUNOLOGY
(2016)
Article
Medicine, General & Internal
Olivia L. Francis, Terry-Ann M. Milford, Cornelia Beldiman, Kimberly J. Payne
JOURNAL OF INVESTIGATIVE MEDICINE
(2016)
Review
Hematology
Huynh Cao, Yi Xu, Rosalia de Necoehea-Campion, David J. Baylink, Kimberly J. Payne, Xiaolei Tang, Christina Ratanatharathorn, Yong Ji, Saied Mirshahidi, Chien-Shing Chen
EXPERIMENTAL HEMATOLOGY
(2017)
Article
Multidisciplinary Sciences
Jacqueline S. Coats, Ineavely Baez, Cornelia Stoian, Terry-Ann M. Milford, Xiaobing Zhang, Olivia L. Francis, Ruijun Su, Kimberly J. Payne
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2017)
Article
Multidisciplinary Sciences
Dequina A. Nicholas, Kangling Zhang, Christopher Hung, Shane Glasgow, Wilson Aruni Aruni, Juli Unternaehrer, Kimberly J. Payne, William H. R. Langridge, Marino De Leon
Article
Pediatrics
Ijeoma Esiaba, Danilyn M. Angeles, Terry-Ann M. Milford, Lorena M. Salto, Kimberly J. Payne, Melissa Y. Kidder, Danilo S. Boskovic
Article
Oncology
Zheng Ge, Qi Han, Yan Gu, Qinyu Ge, Jinlong Ma, Justin Sloane, Guofeng Gao, Kimberly J. Payne, Laszlo Szekely, Chunhua Song, Sinisa Dovat
Article
Oncology
Yali Ding, Bo Zhang, Jonathon L. Payne, Chunhua Song, Zheng Ge, Chandrika Gowda, Soumya Iyer, Pavan K. Dhanyamraju, Glenn Dorsam, Mark E. Reeves, Dhimant Desai, Suming Huang, Kimberly J. Payne, Feng Yue, Sinisa Dovat
Article
Hematology
Chunhua Song, Zheng Ge, Yali Ding, Bi-Hua Tan, Dhimant Desai, Krishne Gowda, Shantu Amin, Raghavendra Gowda, Gavin P. Robertson, Feng Yue, Suming Huang, Vladimir Spiegelman, Jonathon L. Payne, Mark E. Reeves, Zafer Gurel, Soumya Iyer, Pavan Kumar Dhanyamraju, Meixian Xiang, Yuka Imamura Kawasawa, Nathalia M. Cury, Jose Andres Yunes, Mary McGrath, Joe Schramm, Ruijun Su, Yiping Yang, Zhijun Zhao, Xiaoguang Lyu, Markus Muschen, Kimberly J. Payne, Chandrika Gowda, Sinisa Dovat
Review
Biochemistry & Molecular Biology
Parveen Shiraz, Kimberly J. Payne, Lori Muffly
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Letter
Oncology
Huynh Cao, Jeffrey Xiao, Mark E. Reeves, Kimberly Payne, Chien Shing Chen, David J. Baylink, Guido Marcucci, Yi Xu
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2020)
Article
Oncology
Yi Xu, Kimberly Payne, Linh Hoang Gia Pham, Park Eunwoo, Jeffrey Xiao, David Chi, Justin Lyu, Rosalia Campion, Samiksha Wasnik, Il Seok Jeong, Xiaolei Tang, David Jeston Baylink, Chien Shing Chen, Mark Reeves, Mojtaba Akhtari, Saied Mirshahidi, Guido Marcucci, Huynh Cao
TRANSLATIONAL ONCOLOGY
(2020)
Review
Endocrinology & Metabolism
Eunice Nyasani, Iqbal Munir, Mia Perez, Kimberly Payne, Salma Khan